Results of the STAMPEDE and LATITUDE trials, which investigated the addition of abiraterone and prednisone to androgen-deprivation therapy in advanced prostate cancer, have renewed interest in 'complete androgen blockade', a concept originally described by Fernand Labrie in the 1980s. However, whether this treatment regimen should become standard of care remains to be seen.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1702900 (2017).
Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1704174 (2017).
Labrie, F. et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4, 579–594 (1983).
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491–1498 (2000).
Akaza, H. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115, 3437–3445 (2009).
Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742–3748 (2009).
Gillessen, S. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann. Oncol. 26, 1589–1604 (2015).
Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).
James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).
Vale, C. L. et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 17, 243–256 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.T. is an investigator and a paid advisor for Astellas, Bayer, Janssen, and Sanofi-Genzyme. R.J.v.S. declares no competing interests.
Rights and permissions
About this article
Cite this article
Tombal, B., van Soest, R. STAMPEDE, LATITUDE and Fernand Labrie's legacy. Nat Rev Urol 14, 588–590 (2017). https://doi.org/10.1038/nrurol.2017.115
Published:
Issue date:
DOI: https://doi.org/10.1038/nrurol.2017.115
